Latin America HPV Testing And Pap Test Market

Latin America HPV Testing and Pap Test Market Size (2024 to 2029)

The size of the HPV Testing and Pap Test Market in Latin America was around USD 0.30 million in 2024. It is expected to grow at a CAGR of 5.5% to reach USD 0.39 million by 2029. It captures 7% of the global market.

Cancer of the cervix is the second most common cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically shown to be the leading cause of cervical cancer. The Latin America HPV testing and Pap test market drivers include the increasing number of cervical cancer cases, improving medical facilities coupled with the growing number of cervical cancer screening programs, and introducing advanced technologies. HPV is responsible for about 90% of all cervix cancers and 70% of cancers of the genital regions. Pap tests are the preferred test for detecting cervical cancer in routine diagnostics. According to the World Health Organization, Cervical cancer was recorded at an estimated 575,000 new cases in 2019, or 6.8% of all female cancers. These cancers are primarily prevalent in low- and middle-income countries, covering almost 90% of deaths.

Recent advancements include the Point-of-care testing kits, which are primarily error-free and show quick results; these are estimated to drive the Latin America HPV testing and Pap smear market for years to come. Data suggests that a woman has a Pap test every three years from the age of 21. In addition, it is also recommended that women between the ages of 30 and 65 have a Pap and HPV test every five years or a Pap test every three years. Women with certain risk factors may require more frequent screening or continue screening even after 65 years of age. The WHO is working with several local authorities to eradicate the growing cervical cancer rate in 2050 by employing various strategies such as free vaccines, routine screening, and prompt treatment.

However, HPV smear tests cannot detect all HPV infections and are prone to false-negative results. Although, these errors can be corrected by effective molecular diagnostic tests such as the HPV DNA tests. Other factors such as uncertain repayment scenarios and the lack of high-precision POC test kits are expected to hamper the market growth during the study period.

This research report on the Latin America HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories.

Latin America HPV Testing and Pap Test Market Analysis By Test Type

• HPV Testing
• Follow-up HPV Testing
• HPV Primary Testing
• Co-Testing
• PAP Test

Latin America HPV Testing and Pap Test Market Analysis By Application

• Vaginal Cancer Screening
• Cervical Cancer Screening

Latin America HPV Testing and Pap Test Market Analysis By End-users

• Laboratories
• Hospitals
• Physicians
• Offices
• Clinics

Latin America HPV Testing and Pap Test Market Analysis By Country

• Brazil
• Argentina
• Chile
• Mexico
• Rest of Latin America

Geographically, the Brazilian dominated the Latin America HPV testing and Pap test market in terms of revenue in 2023 and is expected to continue throughout the forecast period. The regional market is anticipated to grow at a CAGR of 5.8%, owing to the increase in hospitals and clinics adopting technologically advanced solutions to deliver more accurate and efficient results and awareness programs with local governments for HPV vaccines. The WHO plans to screen 75% of older adults between 35 to 45 years old using Pap smears. The factors mentioned above will show positive growth in the analyzed market.

Argentina is expected to be an attractive market with a CAGR of 6%, followed by Columbia growing with a CAGR of 4.8% during the forecasted period. The Latin American HPV testing and Pap test market will also have lucrative growth in other regional markets of Mexico, Peru, Ecuador, and Puerto Rico, attributed to the increasing healthcare spending, improving healthcare awareness, and continuous technological developments offering better diagnostic services. The latest advancement includes detecting the essential cell-free DNA, which is commonly found in cancer patients and is used as a diagnostic tool in various types of cancer. There have been numerous attempts to detect the HPV DNA (HPV cDNA) in the early screening of cervical cancer. In addition, some researchers are developing a plasma DNA test without HPV cells using ddPCR to detect and monitor the response to treatment of cancers associated with HPV. This development supported with clinical research will drive the market in the Latin American region.

KEY MARKET PLAYERS

Companies playing a vital role in the Latin America HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.